Edaravone
Based on 48 publication(s) in Google Scholar
Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.94%
- No. CAS: 89-25-8
- Fòrmula: C10H10N2O
- Peso molecular:174.20
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Edaravone
More- Nat Neurosci. 2025 Nov 24. [Abstract]
- Adv Funct Mater. 2023 Jul 7.
- Autophagy. 2021 Sep;17(9):2511-2527. [Abstract]
- J Adv Res. 2025 Jun:72:369-385. [Abstract]
- J Nanobiotechnology. 2025 Nov 3;23(1):696. [Abstract]
- Pharmacol Res. 2022 Feb:176:106046. [Abstract]
- Phytomedicine. 2026 Jun:155:158069. [Abstract]
- Phytomedicine. 2025 Sep:145:157011. [Abstract]
- Phytomedicine. 2025 Sep 12:148:157253. [Abstract]
- Phytomedicine. 2025 Jun:141:156649. [Abstract]
- Phytomedicine. 2025 Feb 21:139:156500. [Abstract]
- Phytomedicine. 2025 Jan:136:156331. [Abstract]
- Phytomedicine. 2024 Dec:135:156208. [Abstract]
- NPJ Sci Food. 2025 Nov 3;9(1):216. [Abstract]
- Int J Biol Macromol. 2022 Aug 31:215:398-412. [Abstract]
- Phytother Res. 2024 Jun;38(6):2619-2640. [Abstract]
- Free Radic Biol Med. 2022 Feb 1:179:1-10. [Abstract]
- ACS Appl Mater Interfaces. 2023 Dec 13;15(49):56846-56858. [Abstract]
- Br J Pharmacol. 2026 Jul;183(13):3578-3598. [Abstract]
- Pharmaceutics. 2022 May 25;14(6):1122. [Abstract]
- J Ethnopharmacol. 2026 Jun 28:365:121563. [Abstract]
- J Ethnopharmacol. 2025 Apr 25:346:119664. [Abstract]
- J Ethnopharmacol. 2024 Mar 25:322:117567. [Abstract]
- Eur J Med Chem Rep. 2025 Dec 8;16:100318.
- J Agric Food Chem. 2023 Dec 6;71(48):18986-18998. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70792. [Abstract]
- Life Sci. 2025 Jun 1:370:123568. [Abstract]
- Eur J Pharmacol. 2025 Oct 24.
- Int Immunopharmacol. 2026 Mar 1:172:116182. [Abstract]
- Int Immunopharmacol. 2025 Sep 27:166:115628. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114880. [Abstract]
- Int J Mol Sci. 2022 Aug 14;23(16):9118. [Abstract]
- J Pathol. 2026 Jan;268(1):99-112. [Abstract]
- Nanomaterials. 2024 Dec 6;14(23):1962. [Abstract]
- Front Physiol. 2020 Jan 15:10:1596. [Abstract]
- Curr Issues Mol Biol. 2025 Aug 6;47(8):627. [Abstract]
- Toxicol Appl Pharmacol. 2026 Jun 24:514:117922. [Abstract]
- J Neurorestoratology. 2025 Jul 17.
- J Immunol Res. 2022 Jun 17:2022:6833867. [Abstract]
- Cell Biochem Biophys. 2026 Apr 25. [Abstract]
- Fitoterapia. 2026 Jun:191:107245. [Abstract]
- Biomed Rep. 2026 Jun 24;25(2):99. [Abstract]
- Int Wound J. 2023 Oct;20(8):3088-3104. [Abstract]
- Planta Med. 2017 Feb;83(3-04):341-350. [Abstract]
- Neurol Res. 2025 Sep;47(9):864-875. [Abstract]
- SSRN. 2025 Jan 3.
- Biomed Pharmacother. 2024 May:174:116560. [Abstract]
- Research Square Print. 2023 Feb 14.
-
WB
-
IF
-
IHC
-
Cell Proliferation/Viability Assay
-
IP
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HBMEC-2 | EC50 |
4.61 μM
Compound: Edaravone
|
Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
|
[PMID: 31541868] |
| PC-12 | EC50 |
9.2 μM
Compound: Edaravone
|
Neuroprotective activity against 12.5 mM glutamate-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
Neuroprotective activity against 12.5 mM glutamate-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 28394604] |
| Platelet | IC50 |
0.25 mM
Compound: Eda
|
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
|
[PMID: 22827516] |
| Platelet | IC50 |
0.85 mM
Compound: Eda
|
Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method
|
[PMID: 22827516] |
| ScN2a | IC50 |
>1000 nM
Compound: edaravone
|
Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation
Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation
|
[PMID: 17850126] |
| SH-SY5Y | EC50 |
3.75 μM
Compound: Edaravone
|
Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay
|
[PMID: 31541868] |
Edaravone performs both preventative and therapeutic effects against toxicity of glutamate. Pretreatment of edaravone reduces the toxicity of glutamate towards SGNs. Edaravone reduces apoptosis and necrosis caused by glutamate. Pretreatment of edaravone (500 μM) reverses these changes to approximately normal levels. The protective effect of edaravone on SGNs against glutamate-induced apoptosis is associated with PI3K/Akt pathway and Bcl-2 protein family[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 89-25-8
-
Appearance Solid
-
Peso molecular 174.20
-
Fòrmula C10H10N2O
-
Color Off-white to yellow
-
SMILES
O=C1N(C2=CC=CC=C2)N=C(C)C1
-
Synonyms
MCI-186
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy. [Abstract]2025 Nov 24. PMID: 41286450 -
-
Autophagy
Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence. [Abstract]2021 Sep;17(9):2511-2527. PMID: 33030400 -
J Adv Res
2025 Jun:72:369-385. PMID: 38972542 -
J Nanobiotechnology
Apigenin regulates CCR5/JAK1/STAT1/MMPs signaling to alleviate secondary brain injury after intracerebral hemorrhage and its enhanced delivery via targeted nanoparticles. [Abstract]2025 Nov 3;23(1):696. PMID: 41177867 -
Pharmacol Res
Deoxyhypusine hydroxylase as a novel pharmacological target for ischemic stroke via inducing a unique post-translational hypusination modification. [Abstract]2022 Feb:176:106046. PMID: 35007708 -
Phytomedicine
Huang-Qi-Long-Dan Granule alleviates ischemic stroke injury by regulating the crosstalk between Nrf2 and NF-κB signaling. [Abstract]2026 Jun:155:158069. PMID: 41861685 -
Phytomedicine
The protective mechanism of Hydroxysafflor yellow A for the treatment of stroke - heart - syndrome via activating the ZBP1-NLRP3 signaling pathway. [Abstract]2025 Sep:145:157011. PMID: 40602292 -
Phytomedicine
Moracin N alleviates ischaemic brain injury in mice by suppressing neuronal ferroptosis via the activation of the Keap1/Nrf2 signalling pathway. [Abstract]2025 Sep 12:148:157253. PMID: 40972263 -
Phytomedicine
4-Hydroxyderricin attenuates ischemic brain injury and neuroinflammation by upregulating haptoglobin expression in microglia. [Abstract]2025 Jun:141:156649. PMID: 40117946 -
Phytomedicine
Allicin alleviates traumatic brain injury-induced neuroinflammation by enhancing PKC-δ-mediated mitophagy. [Abstract]2025 Feb 21:139:156500. PMID: 39986225 -
Phytomedicine
Gastrodin: Modulating the xCT/GPX4 and ACSL4/LPCAT3 pathways to inhibit ferroptosis after ischemic stroke. [Abstract]2025 Jan:136:156331. PMID: 39731833 -
Phytomedicine
Salidroside facilitates neuroprotective effects in ischemic stroke by promoting axonal sprouting through promoting autophagy. [Abstract]2024 Dec:135:156208. PMID: 39550919 -
NPJ Sci Food
Astragali Radix-Carthami Flos alleviate brain-heart injury after cerebral ischemia/reperfusion via regulating TSPO signaling. [Abstract]2025 Nov 3;9(1):216. PMID: 41184295 -
Int J Biol Macromol
Microwave assisted extraction, characterization of a polysaccharide from Salvia miltiorrhiza Bunge and its antioxidant effects via ferroptosis-mediated activation of the Nrf2/HO-1 pathway. [Abstract]2022 Aug 31:215:398-412. PMID: 35718160 -
Phytother Res
Salidroside directly activates HSC70, revealing a new role for HSC70 in BDNF signalling and neurogenesis after cerebral ischemia. [Abstract]2024 Jun;38(6):2619-2640. PMID: 38488455 -
Free Radic Biol Med
Hydroxysafflor yellow A and anhydrosafflor yellow B alleviate ferroptosis and parthanatos in PC12 cells injured by OGD/R. [Abstract]2022 Feb 1:179:1-10. PMID: 34923102 -
ACS Appl Mater Interfaces
Photothermal-Ionic-Pharmacotherapy of Myocardial Infarction with Enhanced Angiogenesis and Antiapoptosis. [Abstract]2023 Dec 13;15(49):56846-56858. PMID: 38031235 -
Br J Pharmacol
Cordycepin alleviates ischaemic brain injury by suppressing microglia-induced neuroinflammation via regulating the Notch1 signalling pathway. [Abstract]2026 Jul;183(13):3578-3598. PMID: 41913462 -
Pharmaceutics
Transferrin-Enabled Blood-Brain Barrier Crossing Manganese-Based Nanozyme for Rebalancing the Reactive Oxygen Species Level in Ischemic Stroke. [Abstract]2022 May 25;14(6):1122. PMID: 35745695 -
J Ethnopharmacol
Huangqi Guizhi Wuwu decoction promotes neuroprotection and functional recovery after ischemic stroke via activation of the PI3K/Akt/mTOR signaling pathway and modulation of microglial polarization. [Abstract]2026 Jun 28:365:121563. PMID: 41887379 -
J Ethnopharmacol
Shexiang Tongxin Dropping Pills attenuate ischemic microvascular dysfunction via suppressing P66Shc-mediated mitochondrial respiration deficits. [Abstract]2025 Apr 25:346:119664. PMID: 40154895 -
J Ethnopharmacol
Shexiang Tongxin dropping pills protect against ischemic stroke-induced cerebral microvascular dysfunction via suppressing TXNIP/NLRP3 signaling pathway. [Abstract]2024 Mar 25:322:117567. PMID: 38122909 -
-
J Agric Food Chem
Optimized Separation of Carthamin from Safflower by Macroporous Adsorption Resins and Its Protective Effects on PC12 Cells Injured by OGD/R via Nrf2 Signaling Pathway. [Abstract]2023 Dec 6;71(48):18986-18998. PMID: 37997370 -
CNS Neurosci Ther
Novel Glycyrrhizinic Acid Derivative YCY-20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE-RAGE/MAPK Pathway. [Abstract]2026 Feb;32(2):e70792. PMID: 41700485 -
Life Sci
2025 Jun 1:370:123568. PMID: 40113075 -
-
Int Immunopharmacol
Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis. [Abstract]2026 Mar 1:172:116182. PMID: 41520561 -
Int Immunopharmacol
Emodin facilitates the transformation of A1/A2 reactive astrocytes through the 11β-HSD1/AKT signaling pathway in the context of cerebral ischemia. [Abstract]2025 Sep 27:166:115628. PMID: 41016200 -
Int Immunopharmacol
Edaravone attenuates cerebral inflammation by inhibiting mast cells degranulation via ROS/STIM1 signaling pathway in HIE model. [Abstract]2025 Jun 26:159:114880. PMID: 40394799 -
Int J Mol Sci
Rescue of Mitochondrial SIRT3 Ameliorates Ischemia-like Injury in Human Endothelial Cells. [Abstract]2022 Aug 14;23(16):9118. PMID: 36012382 -
J Pathol
Hypoxia-induced regional heterogeneity in proliferative vitreoretinopathy: implications for targeted therapies. [Abstract]2026 Jan;268(1):99-112. PMID: 41215615 -
Nanomaterials
Synthesis and Antioxidant Effects of Edaravone-Loaded MPEG-2000-DSPE Micelles in Rotenone-Induced PC12 Cell Model of Parkinson's Disease. [Abstract]2024 Dec 6;14(23):1962. PMID: 39683350 -
Front Physiol
Protective Effect of Edaravone Against Oxidative Stress in C2C12 Myoblast and Impairment of Skeletal Muscle Regeneration Exposed to Ischemic Injury in Ob/ob Mice. [Abstract]2020 Jan 15:10:1596. PMID: 32009986
Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15:10:1596. [Abstract]
After treating C2C12 cells with 250 µM H2O2, viability is significantly decreased, and improvement in survival rate was observed in the group treated with Edaravone at 100 µM (∗compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).
Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15:10:1596. [Abstract]
TNF-α expression is significantly increased by treating C2C12 cells with 250 µM H2O2. In addition, pretreatment with edaravone at 100 µM, TNF-α expression is significantly suppressed (∗ compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).
Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15:10:1596. [Abstract]
A) HE staining of muscle tissue after artery ligation shows that the cells are round, and reveals infiltration of inflammatory cells in both control (Con) and ob/ob (Ob) mice. (B) MyoD immunostaining is lower in Ob than Con at 7 days after ligation of the femoral artery. However, pretreatment with Edaravone increases the expression of MyoD in obese mice.
-
Curr Issues Mol Biol
An Integrated Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation Study to Investigate the Potential Mechanism of Isoliquiritigenin in the Treatment of Ischemic Stroke. [Abstract]2025 Aug 6;47(8):627. PMID: 40864781 -
Toxicol Appl Pharmacol
Gastrodin inhibits the dephosphorylation of EGFR by DUSP3 to suppress oxidative stress-induced ferroptosis in astrocytes and alleviate cerebral ischemia-reperfusion injury. [Abstract]2026 Jun 24:514:117922. PMID: 42341951 -
-
J Immunol Res
Targeting Ferroptosis Attenuates Inflammation, Fibrosis, and Mast Cell Activation in Chronic Prostatitis. [Abstract]2022 Jun 17:2022:6833867. PMID: 35755168 -
Cell Biochem Biophys
Sugiol Alleviates Cerebral Ischemia/Reperfusion Injury in the Early Phase Involving the LRRK2/NF-κB Pathway. [Abstract]2026 Apr 25. PMID: 42033589 -
Fitoterapia
Shunaoxin dropping pills alleviate cerebral ischemia-reperfusion injury in MCAO rats associated with ferroptosis inhibition and AKT/Nrf2/HO-1 pathway activation. [Abstract]2026 Jun:191:107245. PMID: 41980682 -
Biomed Rep
Toxicity evaluation and anti-ischemic stroke activity of selected natural extracts in zebrafish. [Abstract]2026 Jun 24;25(2):99. PMID: 42388451 -
Int Wound J
Edaravone promotes viability of random skin flaps via activating PI3K/Akt/mTOR signalling pathway-mediated enhancement of autophagy. [Abstract]2023 Oct;20(8):3088-3104. PMID: 37042039
Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Oct;20(8):3088-3104. [Abstract]
Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly increases the protein expression of TGF-β1, VEGF and MMP9 in mice.
Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Oct;20(8):3088-3104. [Abstract]
Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly reduces the number of apoptotic cells in mice.
Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Oct;20(8):3088-3104. [Abstract]
Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly promotes VEGF and MMP9 expression in mice.
-
Planta Med
2017 Feb;83(3-04):341-350. PMID: 27648557 -
Neurol Res
Exploring neuroprotective effects of PP2 in ischemic stroke via bioinformatics and experimental validation. [Abstract]2025 Sep;47(9):864-875. PMID: 40355807 -
-
Biomed Pharmacother
Mastoparan M promotes functional recovery in stroke mice by activating autophagy and inhibiting ferroptosis. [Abstract]2024 May:174:116560. PMID: 38583338 -
Solvente y solubilidad
DMSO : 100 mg/mL (574.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Cell viability is quantified by MTT assay and trypan blue staining. MTT (5 mg/mL, 20 μL) is added to each well and incubated for 4 h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570 nm using an ELISA reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Yoshida, H., et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev, 2006. 12(1): p. 9-20. [Content Brief]
[2]. Okamura, K., et al. Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. Neurol Res, 2013. [Content Brief]
[3]. Garcia CA, et al. Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus. Childs Nerv Syst. 2016 Dec 17. [Epub ahead of print] [Content Brief]
[4]. Bai X, et al. Protective Effect of Edaravone on Glutamate-Induced Neurotoxicity in Spiral Ganglion Neurons. Neural Plast. 2016;2016:4034218. Epub 2016 Nov 10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.7405 mL | 28.7026 mL | 57.4053 mL | 143.5132 mL |
| 5 mM | 1.1481 mL | 5.7405 mL | 11.4811 mL | 28.7026 mL | |
| 10 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL | 14.3513 mL | |
| 15 mM | 0.3827 mL | 1.9135 mL | 3.8270 mL | 9.5675 mL | |
| 20 mM | 0.2870 mL | 1.4351 mL | 2.8703 mL | 7.1757 mL | |
| 25 mM | 0.2296 mL | 1.1481 mL | 2.2962 mL | 5.7405 mL | |
| 30 mM | 0.1914 mL | 0.9568 mL | 1.9135 mL | 4.7838 mL | |
| 40 mM | 0.1435 mL | 0.7176 mL | 1.4351 mL | 3.5878 mL | |
| 50 mM | 0.1148 mL | 0.5741 mL | 1.1481 mL | 2.8703 mL | |
| 60 mM | 0.0957 mL | 0.4784 mL | 0.9568 mL | 2.3919 mL | |
| 80 mM | 0.0718 mL | 0.3588 mL | 0.7176 mL | 1.7939 mL | |
| 100 mM | 0.0574 mL | 0.2870 mL | 0.5741 mL | 1.4351 mL |